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Objectives: There is still little evidence to support routine dual antiplatelet therapy (DAPT) 26 
with P2Y12 antagonists following coronary artery bypass grafting (CABG). The Arterial Revas-27 
cularization Trial (ART) was designed to compare 10-year survival after bilateral versus single 28 
internal thoracic artery grafting. We aimed to get insights into the effect of DAPT (with 29 
clopidogrel) following CABG on 1 year outcomes by performing a post-hoc ART analysis.  30 
Methods: Among patients enrolled in the ART (n=3102), 609 (21%) and 2308 (79%) were 31 
discharged on DAPT or aspirin alone respectively. The primary endpoint was the incidence of 32 
major adverse cerebrovascular and cardiac events (MACCE) at 1 year including cardiac death, 33 
myocardial infarction, cerebrovascular accident and reintervention; safety endpoint was bleed-34 
ing requiring hospitalization. Propensity score (PS) matching was used to create comparable 35 
groups.  36 
Results: Among 609-PS matched pairs, MACCE occurred in 34 (5.6%) and 34 (5.6%) in the 37 
DAPT and aspirin alone groups respectively with no significant difference between the two 38 
groups (HR 0.97; 95%CI 0.59-1.59; P=0.90). Only 188 (31%) subjects completed 1 year of 39 
DAPT and in this subgroup, MACCE rate was 5.8% (HR 1.11; 95%CI 0.53-2.30; P=0.78).  In 40 
the overall sample, bleeding rate was higher in DAPT group (2.3% versus 1.1%; P=0.02) alt-41 
hough this difference was no longer significant after matching (2.3% vs 1.8%; P=0.54).   42 
Conclusions: Based on these findings, when compared to aspirin alone, DAPT with 43 
clopidogrel prescribed at discharge was not associated with a significant reduction of adverse 44 
cardiac and cerebrovascular events at 1 year following CABG.  45 
Keywords: dual antiplatelet therapy; coronary artery bypass grafting; bleeding46 
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Introduction 47 
Coronary artery bypass grafting (CABG) is widely regarded as the revascularisation strategy 48 
of choice, particularly in patients with multivessel coronary artery disease [1]. However, 49 
CABG patients still have a significant risk of subsequent major adverse cardiovascular events 50 
(MACCE, including mortality, myocardial infarction (MI) stroke and repeat revacularization) 51 
secondary to graft failure and atherosclerosis progression, particularly during the first 12 52 
months. In fact, MACCE rates in the first year after CABG still exceed 12% [2] 53 
The appropriate antiplatelet regimen after CABG remains an area of controversy [3]. Dual 54 
antiplatelet therapy (DAPT) with the addition of an oral P2Y12 antagonist such as Clopidogrel 55 
to aspirin for 1 year after surgery has been proposed to improve outcomes. Plaque stability, 56 
prevention of graft closure, and secondary thrombosis form the basis for using a second an-57 
tiplatelet drug, whereas the increased risk of bleeding and lack of conclusive evidence should 58 
also be considered.  59 
Evidence for use of DAPT following CABG [4] is based mainly on a small proportion of pa-60 
tients undergoing surgical revascularization in landmark trials enrolling acute coronary syn-61 
drome (ACS) patients [5-7]. Whereas cardiac surgeons are very familiar with the guidelines 62 
regarding discontinuation of DAPT prior to CABG to minimize bleeding risks [8,9], there is 63 
considerable variability in DAPT resumption in post CABG [10,11]. 64 
The Arterial Revascularization Trial (ART) was designed to investigate whether bilateral in-65 
ternal thoracic artery (BITA) grafting is associated with improved 10-year survival when com-66 
pared to single internal thoracic artery (SITA) grafting in patients with multivessel disease 67 
undergoing CABG [12] and final results will be available in 2018. We aimed to get insights 68 
into the efficacy and safety of DAPT following CABG on 1 year outcomes by performing a 69 
retrospective analysis of the ART trial.  70 
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Materials and Methods 71 
This research adheres to the principles set forth in the Declaration of Helsinki 72 
(http://www.wma.net/en/30publications/10policies/b3/index.html). For the purpose of the pre-73 
sent analysis, patients enrolled in the ART (n=3102) were classified according to whether they 74 
were discharge on DAPT (with clopidogrel) or aspirin alone following surgery. In the ART, 75 
antiplatelet therapy prescribed at discharge was at discretion of responsible physicians. We 76 
excluded those who met the following criteria: 1) Hospital death; 2) Withdrawn; 3) No infor-77 
mation on antiplatelet therapy at discharge; 4) Clopidogrel alone at discharge. 78 
Trial design 79 
The protocol for the ART has been published [13]. Briefly, the ART is a 2-arm, randomized 80 
multicenter trial conducted in 28 hospitals in 7 countries, with patients being randomized 81 
equally to SITA or BITA grafts. Eligible patients were those with multivessel coronary artery 82 
disease undergoing CABG including urgent patients. Emergency patients (on-going myocar-83 
dial ischemia/cardiogenic shock) and those requiring single grafts or redo CABG were ex-84 
cluded.  85 
Follow-up and Study Endpoints  86 
Questionnaires were sent to study participants by post at 1 year after surgery. No clinic visits 87 
were planned apart from the routine clinical 6-week post-operative visit. Participants were sent 88 
stamped addressed envelopes to improve the return rates of postal questionnaires. Study co-89 
ordinators contacted participants by telephone to alert them to the questionnaire’s arrival and 90 
to ask them about medications, adverse events and health services resource use. 91 
The primary endpoint was the incidence of major adverse cerebrovascular and cardiac events 92 
(MACCE) at 1 year defined as the occurrence of cardiovascular death (CV-death), myocardial 93 
infection (MI), either ST elevation or non ST elevation MI, cerebrovascular accident (CVA) or 94 
5 
repeat revascularization. We also investigated the composite endpoint of cardiac death, MI and 95 
CVA and all-cause mortality. Safety endpoint was bleeding requiring re-hospitalization. Ad-96 
verse events were adjudicated blind to surgical procedure by a member of the Clinical Event 97 
Review Committee. Follow-up at 1 year was available for all patients included in the analysis 98 
(100%).  99 
Statistical analysis 100 
Multiple imputation was used to address missing data (http://www.jstatsoft.org/v45/i07/). Ex-101 
pectation-maximization with bootstrapping algorithm was used to generate 3 imputed datasets. 102 
No prior information was used. Sets of estimates from different datasets were combined using 103 
the Rubin rule: the central estimate corresponds to the mean of individual imputation estimates 104 
and the variance is the weighted sum of two variances: the within imputation variance and the 105 
between imputation variance [14]. Due to lack of randomization with regards to DAPT admin-106 
istration following surgery, a propensity score (PS) was generated for each patient from a mul-107 
tivariable logistic regression model based on pre-treatment covariates as independent variables 108 
with DAPT versus aspirin alone administration as a binary dependent variable [15]. Covariates 109 
included in the PS model were: age, female gender, body mass index (BMI), creatinine, diabe-110 
tes mellitus (DM), smoking, chronic obstructive pulmonary disease (COPD), peripheral vas-111 
cular disease (PVD), left ventricular ejection fraction (LVEF), left main disease (LMD), myo-112 
cardial infarction (MI, including both ST elevation and non ST elevation MI), percutaneous 113 
coronary intervention (PCI), unstable angina (UA), off-pump CABG (OPCAB), use of saphe-114 
nous vein graft (SVG), other medication prescribed at discharge: vitamin K antagonist (VKA), 115 
beta-blockers (BB), angiotensin converting enzyme inhibitor (ACEI) and angiotensin receptor 116 
blocker (ARB).  117 
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Pairs of patients were derived using greedy 1:1 matching with a calliper of width of 0.2 stand-118 
ard deviation of the logit of the PS (http://CRAN.Rproject.org/package=nonrandom). The qual-119 
ity of the match was assessed by comparing selected pre-treatment variables in propensity 120 
score–matched patients using the standardized mean difference (SMD), for which an absolute 121 
standardized difference of greater than 10% is suggested to represent meaningful covariate 122 
imbalance [16]. A Cox regression model, stratified on the matched pairs [14] and adjusted for 123 
other medications at discharge, was used to estimate the treatment effect (i.e. DAPT vs aspirin 124 
alone) on outcomes of interest (http://CRAN.R-project.org/package=survival). This approach 125 
accounts for the within-pair homogeneity by allowing the baseline hazard function to vary 126 
across matched sets. For competing risk adverse event (MI, CVA and repeat revascularization) 127 
a competing risk framework was used (https://CRAN.R-project.org/package=riskRegression). 128 
Potential effect modifiers (interaction terms) examined were: 1) unstable angina, 2) prior MI 129 
within 1 year; 3) prior percutaneous coronary intervention (PCI) within 1 year; 4) off-pump 130 
surgery; and 5) use of saphenous vein graft (SVG). Double robust method (multivariate adjust-131 
ment in the PS matched sample) was used to compute treatment effect estimates within sub-132 
groups. The proportional hazard assumption was tested by graphical inspection using log(-133 
log(S)) method with Kaplan Meier estimators from the PS matched sample. In this case, the 134 
space between the two curves should be constant over time (Supplementary Figure 1 for the 135 
primary endpoint). A goodness of fit test (Schoenfeld residuals) was used to confirm that re-136 
siduals for the treatment variable were not related to time (P=0.49 for the primary endpoint). 137 
A generic binomial test was used for a post-hoc power calculation for the primary end-point. 138 
Time to event analysis were graphically presented as cumulative incidence curves which show 139 
the cumulative probabilities of experiencing the event of interest. Cumulative incidence was 140 
computed as 1-St where St corresponds to the proportion surviving past interval t) obtained 141 
from the life table using the Kaplan-Meier approach. All p-values <0.05 were considered to 142 
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indicate statistical significance. All statistical analysis were performed using R Statistical Soft-143 
ware (version 3.2.3; R Foundation for Statistical Computing, Vienna, Austria). 144 
Results 145 
The final study population consisted of 2917 patients. Of them 609 (21%) and 2308 (79%) 146 
were discharged on DAPT or aspirin alone respectively. Baseline characteristics of the two 147 
groups are reported in Table 1. In particular, patients receiving DAPT were more likely to have 148 
unstable angina and to receive clopidogrel preoperatively. Patients discharged on DAPT were 149 
more likely to have off-pump surgery, to receive SVG and to be discharged on statins and 150 
ACEI/ARB. The use of vitamin K antagonists at discharge was higher in the aspirin group 151 
(Figure 1). After PS matching the two groups were comparable for all pre-treatment variables 152 
investigated (Figure 1).  153 
Efficacy endpoints  154 
Efficacy endpoints in the 609-PS matched pairs are reported in Table 2. The rate of MACCE 155 
was 34 (5.6%) and 34 (5.6%) in the DAPT and aspirin alone groups respectively with no sig-156 
nificant difference between the two groups (HR 0.97; 95%CI 0.59-1.59; P=0.90; Figure 2 left). 157 
The rate of the composite of CV death, MI and stroke was 21 (3.5%) and 29 (4.8%) in the 158 
DAPT and aspirin alone groups (HR 0.71; 95%CI 0.40-1.27; P=0.20; Figure 2 right).  159 
None of the possible effect modifiers showed a significant interaction with MACCE: unstable 160 
angina (β=-0.39±0.70; P=0.57); prior MI (β=0.1 ±0.87; P=0.98) or prior PCI within 1 year (β=-161 
0.04±1.55; P=0.97), OPCAB (β=-0.82±0.69; P=0.23) and use of saphenous vein grafts (β=-162 
0.35±0.97; P=0.71). However, unstable angina, OPCAB and the use of SVG showed larger 163 
coefficients in favor of a benefit from DAPT. In particular, in patients with unstable angina, 164 
DAPT did not significantly influence the risk of MACCE (HRDR 0.90; 95%CI 0.40-2.06; 165 
P=0.81) but was associated with a lower risk for the composite of CV death, MI and CVA 166 
8 
(HRDR 0.42; 95%CI 0.15-1.21; P=0.1). In patients undergoing off-pump surgery, DAPT did 167 
not significantly influence the risk of MACCE (HRDR 0.90; 95%CI 0.50-1.63; P=0.73) but was 168 
associated with a lower risk for the composite of CV death, MI and CVA (HRDR 0.53; 95%CI 169 
0.25-1.11; P=0.09). 170 
Among 609 patients who received DAPT postoperatively, 188 (31%) completed 1 year of 171 
DAPT, 362 (59%) switched to aspirin alone and other 24 (4%) switched to Clopidogrel alone 172 
(unknown for the remaining 35 patients). The rate of MACCE and the composite of CV death, 173 
MI and CVA was 5.8% and 2.7% respectively for those who continued DAPT for 1 year, 3.9% 174 
and 1.7% respectively for those who switched to aspirin alone and 12.5% and 8.3% respec-175 
tively for those who switched to clopidogrel alone. We the analysis was restricted to subjects 176 
who continued DAPT for 1 year (n=188), DAPT did not significantly influence MACCE 177 
(HRDR 1.11[0.53-2.30]; P=0.78) or the composite of death, MI and CVA (HRDR 0.62; 95%CI 178 
0.22-1.69; P=0.34).  179 
Post-hoc power calculation was based on a 2.0 percentage point reduction in MACCE (3.5% 180 
with DAPT vs 5.5% with Aspirin alone) accordingly to a pooled analysis recently published 181 
[3]. The power achieved was 90% (sample size 1218, 5% significance, 2 tails; Supplementary 182 
Figure 2). 183 
Safety endpoint 184 
The rate of major bleeding was significantly higher in patients discharged on DAPT (14/609, 185 
2.3%) when compared to aspirin alone (25/2308, 1.1%) (HR 2.14[1.11-4.11]; P=0.02; Figure 186 
3) although this difference was no longer significant after PS matching (14,2.3% vs 11,1.8%; 187 
HR 1.30; 95%CI 0.58-2.8; P=0.54).   188 
Discussion 189 
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Based on the present post-hoc analysis there is no evidence that DAPT with Clopidogrel can 190 
significantly reduce the rate of MACCE following surgery. However, in subjects admitted with 191 
unstable angina and undergoing off-pump surgery, we found a non-significant trend towards a 192 
larger protective effect from DAPT. DAPT at discharge was associated with an increased risk 193 
of bleeding but bleeding rates were particularly low in both groups.  194 
Definitive guideline recommendations regarding use of DAPT after CABG are currently lack-195 
ing. Evidence for use of DAPT following CABG is based mainly on a small proportion of 196 
patients in three landmark trials enrolling ACS patients [17-19]. Those trials were not ade-197 
quately powered to address the role of DAPT in the post-CABG cohort. Another limitation is 198 
that they studied three different oral P2Y12 antagonists: Clopidogrel, Ticagrelor and Presugel. 199 
Moreover these results are based on post-randomization subsets from single RCTs in which 200 
DAPT was initiated prior to CABG. Therefore the decision to undergo CABG is a post ran-201 
domization event occurring at variable times post randomization. This decision can thus be 202 
influenced by randomized group resulting in potential baseline imbalances between interven-203 
tion and control groups. On the other hand, available trials on DAPT enrolling CABG patients 204 
only present limited design and are largely underpowered to detect significant differences [20-205 
25].   206 
Patients were enrolled into ART from 2004 to 2007 and Clopidogrel was the only P2Y12 antag-207 
onist used in this trial. Prasugrel and Ticagrelor were approved for use in Europe 2009 and 208 
2010 respectively and the question whether DAPT with newer P2Y12 antagonists is more effec-209 
tive remains to be determined. Of note, a recent meta-analysis [3] including 4 CABG-sub-210 
groups ACS RCTs [17-20] (n=3901) and 5 post-elective CABG trials [21-25] (n=986) con-211 
cluded that DAPT resumption with higher intensity P2Y12 antagonists (Prasugrel or Ticagre-212 
lor), but not Clopidogrel, reduces all-cause mortality in ACS patients who have undergone 213 
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CABG. In the ART trial the vast majority of patients with prior MI within 1 year were dis-214 
charged on aspirin alone in contrast with current recommendation to continue DAPT for one 215 
year following ACS regardless of the treatment adopted [4]. This might be partially explained 216 
by the fact that these recommendations have gained popularity after ART recruitment. We 217 
observed that subjects with unstable angina showed a larger benefit from DAPT although this 218 
result was not statistically significant. We also found that a non-significant trend toward better 219 
outcomes with DAPT in subjects undergoing off-pump surgery and those who received SVG 220 
but these subgroup analyses were largely underpowered to detect significant difference.  221 
It has been demonstrated that off-pump CABG is associated with hypercoagulability postop-222 
eratively [26] which can affect graft patency rate in particular with saphenous vein graft. These 223 
patients may benefit more from DAPT than patients operated with conventional surgery alt-224 
hough there is still paucity of evidence with conflicting results reported [24,27].  225 
 There are several limitations of the present study. Although a post-hoc power calculation sug-226 
gested that the present analysis was sufficiently powered to detect a difference in the primary 227 
endpoint (MACCE at 1 year) between the two groups. Subgroup analyses including subjects 228 
presenting with unstable angina or receiving off-pump surgery or SVGs were largely under-229 
powered. Despite PS matching, a residual imbalance cannot be excluded. In particular, we no-230 
ticed that the rate of reintervention was higher in patients discharged on DAPT. This might 231 
partially due to higher prevalence of risk factors for further coronary interventions in this 232 
group. Finally only 31% of subjects initially prescribed on DAPT completed 1 year of treat-233 
ment and this aspect might have underestimated the effect of DAPT.  No data were available 234 
on DAPT duration in subjects who discontinued DAPT and therefore we were unable to dis-235 
criminate the effect of short (3-6 months) versus long (1 year) DAPT. We performed a sensi-236 
tivity analysis including only subjects who completed 1 year of DAPT and DAPT was con-237 
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firmed to not be associated with better outcomes. We observed that the vast majority of bleed-238 
ing occurred during the first two months from discharge thus supporting the hypothesis that 239 
also short term DAPT following CABG may increase the risk of bleeding.   240 
In conclusion, based on these findings, there is no evidence of a significant benefit from DAPT 241 
with clopidogrel over aspirin alone following CABG. However, the present analysis was un-242 
derpowered to investigate the effect of DAPT in high risk subgroups such as patients with 243 
ACS. Large prospective RCTs evaluating the use of DAPT post-CABG with higher intensity 244 
P2Y12 antagonists are urgently needed to provide more definitive guidance for clinicians. 245 
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Figures Legends 248 
Figure 1. Standardized mean difference (SMD) for baseline variables before and after pro-249 
pensity score matching. (DAPT: dual antiplatelet therapy; SMD: standardized mean differ-250 
ence; PS: propensity score; BMI: body mass index; DM: diabetes mellitus; COPD: chronic 251 
obstructive pulmonary disease. PVD: peripheral vascular disease; MI: myocardial infarction; 252 
PCI: percutaneous coronary intervention; UA: unstable angina; LVEF: left ventricular ejec-253 
tion fraction; AF: atrial fibrillation; SVG: saphenous vein graft; OPCAB: off-pump coronary 254 
artery bypass; VKA: Vitamin K antagonist; BB: beta-blocker; ACEI: angiotensin converting 255 
enzyme inhibitor; ARB: angiotensin receptor blocker) 256 
Figure 2. Cumulative incidence with relative 95% confidence bands of major cerebrovascular 257 
and cardiac events (MACCE, right) and of composite of cardiac death/myocardial infarction 258 
(MI) and cerebrovascular accident (left) in patients discharged on dual antiplatelet therapy 259 
(DAPT) or aspirin alone.  260 
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Figure 3. Cumulative incidence with relative 95% confidence bands of bleeding requiring 261 
hospitalization in patients discharged on dual antiplatelet therapy (DAPT) or aspirin alone.  262 
Supplementary Figure 1. Proportional hazard assumption tested by graphical inspection using 263 
log(-log(S)) method with Kaplan Meier estimators from the matched sample.  264 
Supplementary Figure 2. Graphical representation of post-hoc power calculation for the pri-265 
mary end-point.   266 
267 
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Table 1. Baseline and operative characteristics of patients discharged on dual antiplatelet 268 
therapy (DAPT) or aspirin alone.  269 





n  609 2308  609  
Age (mean (sd))  62.9 (9.4) 62.9 (8.7) 0.006 63.3(8.4) 0.052 
Female n(%) 73 (12.0) 331 (14.3) 0.070 78 (12.8) 0.025 
BMI (mean (sd))  27.9(4.4) 28.3(3.9) 0.110 28.0 (4.0) 0.027 
Creatinine (mean (sd))  101.2 (19.3) 95.1 (21.3) 0.301 101.2 (23.1) 0.001 
DM n(%) 164 (26.9) 531 (23.0) 0.091 158 (25.9) 0.022 
Smoking n(%) 86 (14.1) 334 (14.5) 0.010 75 (12.3) 0.053 
COPD n(%) 47 ( 7.7) 131 ( 5.7) 0.082 42 ( 6.9) 0.032 
PVD n(%) 49 ( 8.0) 152 ( 6.6) 0.056 50 ( 8.2) 0.006 
Prior stroke n(%) 13 ( 2.1) 68 ( 2.9) 0.052 12 ( 2.0) 0.012 
LVEF<.50 n(%) 136 (22.3) 582 (25.2) 0.068 141 (23.2) 0.020 
LMD n(%)  112 (18.4) 498 (21.6) 0.080 134 (22.0) 0.090 
MI within 1Y n(%) 149 (24.5) 541 (23.4) 0.024 156 (25.6) 0.027 
PCI within 1Y n(%) 28 (4.6) 265 (11.5) 0.255 32 ( 5.3) 0.030 
UA n(%) 252 (41.4) 726 (31.5) 0.207 236 (38.8) 0.054 
Preop aspirin n(%) 534 (87.7) 1989 (86.2) 0.045 539 (88.5) 0.025 
Preop clopidogrel n(%)  236 (38.8) 462 (20.0) 0.420 210 (34.5) 0.089 
OPCAB n(%) 430 (70.6) 760 (32.9) 0.814 423 (69.5) 0.025 
SVG n(%) 496 (81.4) 1751 (75.9) 0.136 491 (80.6) 0.021 
N grafts (mean (sd))  3.3 (0.9) 3.1 (0.8) 0.224 3.3 (0.9) 0.038 
Postop VKA n(%)  6 ( 1.0) 87 ( 3.8) 0.184 10 ( 1.6) 0.058 
Postop BB n(%)  501 (82.3) 1949 (84.4) 0.059 501 (82.3) <0.001 
Postop Statins n(%)  581 (95.4) 2118 (91.8) 0.149 578 (94.9) 0.023 
Postop ACEI/ARB n(%)  359 (58.9) 1130 (49.0) 0.201 348 (57.1) 0.037 
DAPT: dual antiplatelet therapy; SMD: standardized mean difference; PS: propensity score; 270 
BMI: body mass index; DM: diabetes mellitus; COPD: chronic obstructive pulmonary disease. 271 
PVD: peripheral vascular disease; MI: myocardial infarction; PCI: percutaneous coronary in-272 
tervention; UA: unstable angina; LVEF: left ventricular ejection fraction; AF: atrial fibrillation; 273 
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SVG: saphenous vein graft; OPCAB: off-pump coronary artery bypass; VKA: Vitamin K an-274 
tagonist; BB: beta-blocker; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin 275 
receptor blocker276 
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Table 2. Outcomes in matched patients discharged on dual antiplatelet therapy (DAPT) or as-277 
pirin alone.  278 
 DAPT Aspirin 
(matched) 
DAPT effect* 
N 609 609  
MACCE n(%) 34(5.6) 34(5.6) 0.97[0.59-1.59] 
CV death/MI/CVA n(%) 21(3.5) 29(4.8) 0.71[0.40-1.27] 
Mortality n(%) 7(1.2) 9(1.5) 0.78[0.29-2.1] 
CV mortality n(%) 5(0.8) 8(1.3) 0.63[0.21-1.91] 
MI n(%) 11(1.8) 13(2.1) 0.84[0.37-1.90] 
CVA n(%) 9(1.5) 12(2.0) 0.75[0.31-1.78] 
Repeat revascularization n(%) 17(2.7) 9(1.5) 1.91[0.85-4.33] 
*Estimates obtained with Cox models stratified by PS-matched pairs and competing risk frame-279 
work for MI, CVA and repeat revascularization.   280 
DAPT: dual antiplatelet therapy; MACCE: major cardiac and cerebrovascular events; CV-281 
death: cardiovascular death; MI: myocardial infarction; CVA: cerebrovascular accident   282 
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